923036-30-0 (N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H,N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7-(p-tolylsulfonyl)pyrrolo[2,3-d]pyrimidin-4-amine)

CAS号:
923036-30-0
中文名称:
N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H
英文名称:
N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7-(p-tolylsulfonyl)pyrrolo[2,3-d]pyrimidin-4-amine
分子式:
C27H31N5O2S
分子量:
489.632344484329

N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H(923036-30-0)名称与标识符

名称

中文别名:
N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H-吡咯并[2,3-D]嘧啶-4-胺;N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺;托法替尼 intB3;托法替尼中间体1;N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H;N-甲基-N-[(3R,4R)-4-甲基-1-(苯基甲基)-3-哌啶基]-7-[(4-甲基苯基)磺酰基]-7H-吡咯并[2,3-d]嘧啶-4-胺;
英文别名:
7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7-[(4-met hylphenyl)sulfonyl]-;N-((3R,4R)-1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7-[(4-met hylphenyl)sulfonyl;7H-Pyrrolo[2,3-d]pyrimidin-4-amine,N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7-[(4-methylphenyl)sulfonyl]-;7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]-;Tofacitinib Impurity 13;GWMBPMUFLFJILW-UHFFFAOYSA-N;N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl- 7H-pyrrolo[2,3-d]pyrimidin-4-amine;N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine;BCP21110;AK544656;N-(1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3;N-(1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-ami;N-(1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-amine;N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (ACI);N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7-(p-tolylsulfonyl)pyrrolo[2,3-d]pyrimidin-4-amine;GWMBPMUFLFJILW-BWKNWUBXSA-N;SCHEMBL1376989;[(3R,4R)-1-benzyl-4-methyl-piperidin-3-yl]-methyl-[7-(4-methyl-benzenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;Rel-N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7-[(4-methylphenyl)sulfonyl]-;2268033-54-9;DS-19344;CS-M2654;YWT8L388ED;N-[(3R,4R)-1-benzyl-4-methylpiperidin-3-yl]-N-methyl-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-amine;923036-30-0;C27H31N5O2S;MFCD28167902;YLB03630;AKOS030632762;

标识符

MDL:
MFCD28167902
InChIKey:
GWMBPMUFLFJILW-BWKNWUBXSA-N
Inchi:
1S/C27H31N5O2S/c1-20-9-11-23(12-10-20)35(33,34)32-16-14-24-26(28-19-29-27(24)32)30(3)25-18-31(15-13-21(25)2)17-22-7-5-4-6-8-22/h4-12,14,16,19,21,25H,13,15,17-18H2,1-3H3/t21-,25+/m1/s1
SMILES:
S(C1C=CC(C)=CC=1)(N1C=CC2C(=NC=NC1=2)N([C@@H]1[C@H](C)CCN(CC2C=CC=CC=2)C1)C)(=O)=O

N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H(923036-30-0)物化性质

实验特性

  • 熔点 : 180-183℃

计算特性

  • 精确分子量 : 489.21984642g/mol
  • 氢键供体数量 : 0
  • 氢键受体数量 : 6
  • 可旋转化学键数量 : 6
  • 同位素质量 : 489.21984642g/mol
  • 重原子数量 : 35
  • 复杂度 : 790
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 2
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 5.2
  • 拓扑分子极性表面积 : 79.7

N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H(923036-30-0)安全信息

N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H(923036-30-0)推荐厂家 更多厂家(20)

N-甲基-N-((3R,4R)-4-甲基-1-苄基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H(923036-30-0)合成路线

合成路线:1 步
反应条件:
参考文献:
Process for the preparation of tofacitinib citrate intermediate N-methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Industrialized production of Tofacitinib citrate
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Isoxazole derivative that inhibits activity of janus kinases (jaks)
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
An Improved and Efficient Process for the Preparation of Tofacitinib Citrate
Patil, Yogesh S.; Bonde, Nilesh L.; Kekan, Ankush S.; Sathe, Dhananjay G.; Das, Arijit, Organic Process Research & Development, 2014, 18(12), 1714-1720
合成路线:1 步
反应条件:
参考文献:
Synthesis and evaluation of tofacitinib analogs designed to mitigate metabolic activation
Tateishi, Yasuhiro ; Shibazaki, Chikako; Takahashi, Kyoko ; Nakamura, Shigeo ; Kazuki, Yasuhiro; et al, Drug Metabolism and Pharmacokinetics, 2022, 43,
合成路线:1 步
反应条件:
参考文献:
Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
Jiang, Jian-kang; Ghoreschi, Kamran; Deflorian, Francesca; Chen, Zhi; Perreira, Melissa; et al, Journal of Medicinal Chemistry, 2008, 51(24), 8012-8018
合成路线:1 步
反应条件:
参考文献:
Preparation method of tofacitinib as JAK inhibitor with high yield
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Process for preparation of piperidinylaminopyrrolopyrimidines from activated pyrrolopyrimidines and piperidinylamines.
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of tofacitinib intermediate
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Process for the preparation of tofacitinib citrate
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Method for preparing N-methyl-N-(4-methylpiperidin)-3-yl-7H-pyrrolopyrimidin-4-amine
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of heteroaromatic compounds for treating autoimmune or proliferative diseases
, China, , ,
合成路线:1 步
反应条件:
参考文献:
A process for the preparation of 1-benzyl-N,4-dimethylpiperidin-3-amine, an useful intermediate for preparation of tofacitinib
, India, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of tofacitinib citrate
, China, , ,
合成路线:1 步
反应条件:
参考文献:
A process for the preparation of tofacitinib and intermediates thereof
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Improved process for preparation of tofacitinib and its citrate using a metal/pivalic acid catalytic system in the debenzylation of N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidi n-4-amine
, India, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of tofacitinib or salts thereof
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of tofacitinib citrate and intermediate thereof
, China, , ,